MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections

Cong, Binbin, Martin, Tracey ORCID: https://orcid.org/0000-0003-2690-4908, Cao, Xiaoshan, Ruge, Fiona, Li, Amber, Mansel, Robert, Wang, Yongsheng and Jiang, Wen ORCID: https://orcid.org/0000-0002-3283-1111 2026. MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 10.2147/bctt.s565199

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (6MB)

Abstract

Introduction: The Metastatic Lymph Node Gene 51 Protein (MLN51), also known as the Cancer Susceptibility Candidate Gene 3 Protein, was first identified in malignant breast tumours. It has been shown to be a key component of the exon junction complex. This study aimed to evaluate the prognostic value of MLN51 expression in breast cancer. Methods: MLN51 expression was evaluated in a Cardiff clinical breast cancer cohort (n = 127) and in The Cancer Genome Atlas breast cancer database. The MLN51 protein was detected by immunohistochemistry. Two groups of breast cancer cell line models were created, namely MLN51 expression activation by transcriptional activation in MLN51 negative cells, and MLN51 knockdown by shRNA in MLN51 positive cells. Cell models were used to study the effect of the expression of the MLN51 gene in their behavior. Results: High expression of the MLN51 transcript was significantly correlated with favourable overall survival and disease free survival (p = 0.004 and p = 0.001, respectively). Patients who responded to chemotherapy had significantly higher MLN51 levels than those who resisted treatment (p = 0.00054), and this connection was more profound in ERBB2 negative type. Following activation of MLN51 in MDA MB-231cells, there was a significant decrease in the growth rate. In contrast, the knockdown of MLN51 in SKBR3 cells significantly increased cell growth. High expression of MLN51 following transcriptional activation increases the sensitivity to chemotherapy and anti-ERBB2 target therapy. Conclusion: MLN51 expression is an independent predictor of disease prognosis, patient survival, and treatment response in breast cancer patients.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Taylor and Francis Group
ISSN:	1179-1314
Date of First Compliant Deposit:	19 January 2026
Date of Acceptance:	5 January 2026
Last Modified:	19 Jan 2026 11:01
URI:	https://orca.cardiff.ac.uk/id/eprint/183984

Actions (repository staff only)

Edit Item